NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Informations projet

NORATEST

N° de convention de subvention: 887507

DOI

10.3030/887507

Projet clôturé

Date de signature de la CE 19 Novembre 2019

Date de début 1 Decembre 2019

Date de fin 31 Mars 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

ALZOHIS
France

Periodic Reporting for period 1 - NORATEST (NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management)

Période du rapport: 2019-12-01 au 2020-03-31

Résumé du contexte et des objectifs généraux du projet

Alzheimer’s disease (AD) is one of the most common diseases in the ageing population, ranking as the fifth leading cause of death. It affects more than 50 Million people worldwide and generates annual expenses near to €1 Trillion in total caring costs. Current tools to diagnose AD are expensive, inaccurate, invasive and in most cases, they are able to detect the disease only at advanced stages, which reduce the chances of treatment. With NoraTest, ALZOHIS will provide a timely and cost-effective method for AD diagnosis, which will allow the detection of symptoms earlier than the current methods, thus reducing the impact and cost of AD on society. NoraTest is based in a simple blood test analysis coupled to an analytical algorithm which provides an accurate score regarding the possibility of having AD.
The goal of this feasibility study was to assess the viability of NoraTest from a technical, regulatory, commercial and financial perspective. Our study shows that NoraTest is a solid project that will generate important benefits for our company. By 2025, ALZOHIS expects cumulative gross profits of over €28 Million, with a payback period of less than 4 years.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During Phase 1 of NoraTest project we analyzed the technical features of our product and determined which improvements are needed to obtain a highly accurate and predictive algorithm for the diagnostic of Alzheimer’s disease. Moreover, we designed a development plan complying with all regulatory policies for the commercialization of NoraTest in the EU and US. We carefully analyzed the market with its trends and barriers. We developed a detailed exploitation and dissemination plan and a strong IPR strategy to protect our invention. Finally, we performed a financial analysis demonstrating that NoraTest project is profitable with an expected 5-years ROI of 1.73.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

With an additional investment of €2.9 Million, we will be able to complete NoraTest project for international commercialization. We expect to launch NoraTest in France by Q4 2020 and then expand to the rest of Europe and the US. We expect a total revenue of €18.2 Million by 2025, while generating 10 new job positions. Besides, by introducing NoraTest onto the market, we will provide an accurate tool for early detection of Alzheimer’s disease which will positively impact patients, families, the healthcare system and even neurobiology research.

noratest-img.png